Skip to main content

Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers

Breast Cancer Research and Treatment volume 175, pages 443–449 (2019)Cite this article

Abstract

Purpose

Following a diagnosis of breast cancer, BRCA mutation carriers face an increased risk of developing a second (contralateral) cancer in the unaffected breast. It is important to identify predictors of contralateral cancer in order to make informed decisions about bilateral mastectomy. The impact of bilateral salpingo-oophorectomy (i.e., oophorectomy) on the risk of developing contralateral breast cancer is unclear. Thus, we conducted a prospective study of the relationship between oophorectomy and the risk of contralateral breast cancer in 1781 BRCA1 and 503 BRCA2 mutation carriers with breast cancer.

Methods

Women were followed from the date of diagnosis of their first breast cancer until the date of diagnosis of a contralateral breast cancer, bilateral mastectomy, date of death, or date of last follow-up. Cox proportional hazards regression was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) of contralateral breast cancer associated with oophorectomy. Oophorectomy was included as a time-dependent covariate. We performed a left-censored analysis for those women who reported a primary breast cancer prior to study entry (i.e., from completion of baseline questionnaire).

Results

After an average of 9.8 years of follow-up, there were 179 (7.8%) contralateral breast cancers diagnosed. Oophorectomy was not associated with the risk of developing a second breast cancer (HR 0.92; 95% CI 0.68–1.25). The relationship did not vary by BRCA mutation type or by age at diagnosis of the first breast cancer. There was some evidence for a decreased risk of contralateral breast cancer among women with an ER-positive primary breast cancer, but this was based on a small number of events (n = 240).

Conclusion

Overall, our findings suggest that oophorectomy has little impact on the risk of contralateral breast cancer.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ et al (2015) Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv033

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kotsopoulos J, Huzarski T, Gronwald J et al (2017) Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv217

    Article  PubMed  Google Scholar 

  3. Domchek SM, Friebel TM, Singer CF et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967–975

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Finch AP, Lubinski J, Moller P et al (2014) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32(15):1547–1553

    Article  PubMed  PubMed Central  Google Scholar 

  5. Metcalfe K, Gershman S, Lynch HT et al (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 104(9):1384–1392

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mavaddat N, Peock S, Frost D et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812–822

    Article  CAS  PubMed  Google Scholar 

  7. Mavaddat N, Barrowdale D, Andrulis IL et al (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomark Prev 21(1):134–147

    Article  CAS  Google Scholar 

  8. Basu NN, Ingham S, Hodson J et al (2015) Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Fam Cancer 14(4):531–538

    Article  CAS  PubMed  Google Scholar 

  9. Weitzel JN, Robson M, Pasini B et al (2005) A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomark Prev 14(6):1534–1538

    Article  CAS  Google Scholar 

  10. Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416

    Article  CAS  PubMed  Google Scholar 

  11. Narod SA, Tung N, Lubinski J et al (2014) A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers. Curr Oncol 21(2):64–68

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge the study staff, students, and volunteers including Shana Kim, Farah Shoukat, Ellen MacDougall, Zoella Pasta, Nida Mian, Jennifer Ng, Sarah Chin, Hamida Begum, Harmeet Chaudhary, Asrafi Azmi, Shahana Nargis, Clotilde Ngwa, Mai Abdelhadi, Saiveena Penikalapati, Laavanya Somasundaram, and Hannah Horvath who helped with the data collection and data entry.

Other members of the Hereditary Breast Cancer Clinical Study Group: Tuya Pal, Georgia Wiesner, Charis Eng, Louise Bordeleau, Eitan Friedman, Wendy Meschino, Carrie Snyder, Kelly Metcalfe, Aletta Poll, Nicole Gojska, Ellen Warner, Barry Rosen, Jeanna McCuaig, Susan Armel, Rochelle Demsky, Karen Panabaker, Linda Steele, Howard Saal, Marie Wood, Wendy McKinnon, Edmond Lemire, Kim Serfas, Kevin Sweet, Seema Panchal, Christine Elser, Carey A. Cullinane, Robert E. Reilly, Joanne L. Blum, Ava Kwong, Cezary Cybulski, Tomasz Huzarski, Daniel Rayson, Claudine Isaacs, Teresa Ramón y Cajal, Jeffrey Dungan, Dana Zakalik, and Stephanie Cohen.

Funding

Joanne Kotsopoulos is a recipient of a Tier II Canada Research Chair. Steven A. Narod is the recipient of a Tier I Canada Research Chair. This study was supported by a Canadian Cancer Society Research Institute Grant (703058), the Peter Gilgan Foundation, and by a “Pink ribbon” grant (194751) from Den Norske Kreftforening to E.H.

Author information

Authors and Affiliations

  1. Women’s College Research Institute, Women’s College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada

    Joanne Kotsopoulos, Ping Sun & Steven A. Narod

  2. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

    Joanne Kotsopoulos & Steven A. Narod

  3. International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland

    Jan Lubinski & Jacek Gronwald

  4. Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, NE, USA

    Henry T. Lynch

  5. Beth Israel Deaconess Medical Center, Boston, MA, USA

    Nadine Tung

  6. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada

    Susan Armel

  7. Division of Human Genetics, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA

    Leigha Senter

  8. Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

    Christian F. Singer

  9. Department of Medicine and Surgery, University of Milan Bicocca, Milan, Italy

    Robert Fruscio

  10. Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

    Fergus Couch

  11. Division of Clinical Cancer Genomics, Department of Population Sciences, City of Hope, Duarte, CA, USA

    Jeffrey N. Weitzel

  12. Gynecology Oncology, Cedars Sinai Medical Center, Los Angeles, CA, USA

    Beth Karlan

  13. Program in Cancer Genetics, Department of Oncology and Human Genetics, McGill University, Montreal, QC, Canada

    William D. Foulkes

  14. Inherited Cancer Research Group, Department for Medical Genetics, Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

    Pal Moller

  15. Toronto-Sunnybrook Regional Cancer Center, Toronto, ON, Canada

    Andrea Eisen

  16. Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada

    Peter Ainsworth

  17. Division of Biomarkers of Early Detection and Prevention, Department of Population Science, City of Hope, Duarte, CA, USA

    Susan L. Neuhausen

  18. Department of Medicine and Human Genetics, University of Chicago, Chicago, IL, USA

    Olufunmilayo Olopade

Authors
  1. Joanne Kotsopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Lubinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henry T. Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nadine Tung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susan Armel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Leigha Senter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christian F. Singer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Robert Fruscio
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fergus Couch
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jeffrey N. Weitzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Beth Karlan
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. William D. Foulkes
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Pal Moller
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Andrea Eisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Peter Ainsworth
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Susan L. Neuhausen
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Olufunmilayo Olopade
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Ping Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Jacek Gronwald
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Steven A. Narod
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

the Hereditary Breast Cancer Clinical Study Group

Corresponding author

Correspondence to Steven A. Narod.

Ethics declarations

Conflict of interest

All the authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The other members of the Hereditary Breast Cancer Clinical Study Group are listed in the Acknowledgments.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kotsopoulos, J., Lubinski, J., Lynch, H.T. et al. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 175, 443–449 (2019). https://doi.org/10.1007/s10549-019-05162-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-019-05162-7

Keywords

  • BRCA1/2
  • Oophorectomy
  • Contralateral breast cancer